Patient-reported outcomes from the phase III, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/ KEYNOTE-A18 Study of pembrolizumab plus concurrent chemoradiotherapy among patients with high-risk, locally advanced cervical cancer

被引：0

作者：

Randall, Leslie ^{[1
]}

Sukhin, Vladyslav ^{[2
]}

Colombo, Nicoletta ^{[3
,4
]}

Korach, Jacob ^{[5
]}

Matsumoto, Takashi ^{[6
]}

Lalondrelle, Susan ^{[7
]}

Vizkeleti, Julia ^{[8
]}

Samouelian, Vanessa ^{[9
]}

Salani, Ritu ^{[10
]}

Salman, Pamela ^{[11
]}

Nogueira-Rodrigues, Angelica ^{[12
]}

Ayhan, Ali ^{[13
]}

Frentzas, Sophia ^{[14
,15
]}

Cueva, Juan ^{[16
]}

Kim, Yong-Man ^{[17
]}

Petru, Edgar ^{[18
]}

Milla, Dency Pilar ^{[19
]}

Sehouli, Jalid ^{[20
]}

Saevets, Valeriya ^{[21
]}

Yamada, Karin ^{[22
]}

Li, Kan ^{[23
]}

Szamreta, Elizabeth ^{[22
]}

Nguyen, Allison Martin ^{[22
]}

Pignata, Sandro ^{[24
]}

Lorusso, Domenica ^{[25
]}

机构：

[1] Virginia Commonwealth Univ, Richmond, VA USA

[2] Grigoriev Inst Med Radiol & Oncol, Kharkiv, Ukraine

[3] Univ Milano Bicocca, Milan, Italy

[4] European Inst Oncol IRCCS, Milan, Italy

[5] Sheba Med Ctr, Tel Aviv, Israel

[6] Ehime Univ, Matsuyama, Ehime, Japan

[7] Royal Marsden, London, England

[8] Natl Inst Oncol, Ctr Radiotherapy, Budapest, Hungary

[9] Univ Montreal, Montreal, PQ, Canada

[10] Univ Calif Los Angeles, Los Angeles, CA USA

[11] Oncovida Canc Ctr, Santiago, Chile

[12] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil

[13] Baskent Univ, Turkish Soc Gynecol Oncol TRSGO, Ankara, Turkiye

[14] Monash Hlth, Melbourne, Vic, Australia

[15] Monash Univ, Melbourne, Vic, Australia

[16] Hosp Clin Univ Santiago Compostela, Dept Med Oncol, Santiago De Compostela, Spain

[17] Univ Ulsan, Asan Med Ctr, Seoul, South Korea

[18] Med Univ Graz, Graz, Austria

[19] Hosp Nacl Guillermo Almenara Irigoyen, Lima, Peru

[20] Charite Univ Med Berlin, Berlin, Germany

[21] Chelyabinsk Reg Clin Ctr Oncol & Nucl Med, Chelyabinsk, Russia

[22] Merck & Co Inc, Rahway, NJ 07065 USA

[23] Merck & Co Inc, N Wales, PA USA

[24] Inst Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy

[25] Univ Cattolica Sacro Cuore, Rome, Italy

来源：

GYNECOLOGIC ONCOLOGY | 2024年 / 190卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S9 / S9

页数：1

共 50 条

[21] Phase-III-Study for local or locally advanced Prostate Cancer Randomized, double-blind, placebo-controlled Phase-III-Study of Apalutamide in Patients with local High-Risk Prostate Cancer or locally advanced Prostate Cancer receiving primary radiotherapy (ATLAS) - study AP 90/15 of the AUO
Rexer, H.
Graefen, M.
UROLOGE, 2017, 56 (02): : 243 - 244
[22] Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial
Burris, Howard A., III
Okusaka, Takuji
Vogel, Arndt
Lee, Myung Ah
Takahashi, Hidenori
Breder, Valeriy
Blanc, Jean-Frederic
Li, Junhe
Bachini, Melinda
Zotkiewicz, Magdalena
Abraham, Jayne
Patel, Nikunj
Wang, Julie
Ali, Muzammil
Rokutanda, Nana
Cohen, Gordon
Oh, Do-Youn
LANCET ONCOLOGY, 2024, 25 (05): : 626 - 635
[23] Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
Harrington, Kevin
Temam, Stephane
Mehanna, Hisham
D'Cruz, Anil
Jain, Minish
D'Onofrio, Ida
Manikhas, Georgy
Horvath, Zsuzsanna
Sun, Yan
Dietzsch, Stefan
Dubinsky, Pavol
Holeckova, Petra
El-Hariry, Iman
Franklin, Natalie
Biswas-Baldwin, Nigel
Legenne, Philippe
Wissel, Paul
Netherway, Thelma
Farrell, John
Ellis, Catherine
Wang-Silvanto, Jing
Amonkar, Mayur
Ahmed, Nazma
Santillana, Sergio
Bourhis, Jean
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (35) : 4202 - +
[24] Phase III Study for local or locally advanced Prostate Cancer: Randomized, double-blind, Placebo-controlled Phase 3 Study of Apalutamide in Patients with local High-Risk Prostate Cancer or locally advanced Prostate Cancer receiving primary Radiotherapy (ATLAS) - Study AP 90/15 of the AUO
Rexer, H.
Graefen, M.
Grimm, M. -O.
AKTUELLE UROLOGIE, 2017, 48 (06) : 520 - +
[25] Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase III, randomized, double-blind, placebo-controlled study (ARASTEP)
Morgans, A. K.
Gschwend, J. E.
Shore, N. D.
Ross, A.
Feng, F.
Hope, T.
Trandafir, L.
Le Berre, M-A.
Kuss, I.
Joensuu, H.
Fizazi, K.
ANNALS OF ONCOLOGY, 2023, 34 : S997 - S998
[26] KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer
Rugo, Hope S.
Sohn, Joohyuk
Jerez Gilarranz, Yolanda
Gonzalez-Cortijo, Lucia
Sonnenblick, Amir
Sabanathan, Dhanusha
Pablo Korbenfeld, Ernesto
Egle, Daniel
Poirier, Brigitte
Zagouri, Flora
Matikas, Alexios
Aksoy, Sercan
Demirci, Umut
Ramos-Elias, Pier
Im, Seock-Ah
Cardoso, Fatima
Jia, Liyi
Baccan, Carlos
Tryfonidis, Konstantinos
Schmid, Peter
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[27] KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer
Schmid, Peter
Baccan, Carlos
Guo, Zifang
Tryfonidis, Kostas
Rugo, Hope S.
CANCER RESEARCH, 2022, 82 (04)
[28] eVOLVE-Cervical (GOG-3092/ENGOT-cx19/GEICO133-C): A prospective phase III study of volrustomig versus placebo after definitive chemoradiation among women with high-risk, locally advanced cervical cancer
Randall, Leslie
Wu, Xiaohua
Mayadev, Jyoti
Takekuma, Munetaka
Estevez-Diz, Maria Del Pilar
Shapira-Frommer, Ronnie
Rimel, Bobbie
Lorusso, Domenica
Lee, Jung-Yun
Zhou, Qi
Zeng, Xiaoling
Huang, Rochelle
Krug, Lee
Oaknin, Ana
GYNECOLOGIC ONCOLOGY, 2024, 190 : S285 - S285
[29] Darolutamide plus androgen-deprivation therapy in patients with high-risk biochemical recurrence of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP)
Chehrazi-Raffle, Alex
Morgans, Alicia K.
Gschwed, Jurgen E.
Shore, Neal D.
Ross, Ashley
Feng, Felix Y.
Hope, Thomas A.
Nordquist, Luke
Niazi, Tamim
Trandafir, Lucia
Le Berre, Marie-Aude
Kuss, Iris
Joensuu, Heikki
Fizazi, Karim
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[30] Phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer (mBC): KEYNOTE-B49
Schmid, Peter
Sohn, Joo Hyuk
Jerez Gilarranz, Yolanda
Gonzalez-Cortijo, Lucia
Sonnenblick, Amir
Sabanathan, Dhanusha
Korbenfeld, Ernesto
Egle, Daniel
Poirier, Brigitte
Zagouri, Flora
Matikas, Alexios
Aksoy, Sercan
Demirci, Umut
Ramos-Elias, Pier
Im, Seock-Ah
Cardoso, Fatima
Jia, Liyi
Hirshfield, Kim
Tryfonidis, Konstantinos
Rugo, Hope S.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 233 - 234

← 1 2 3 4 5 →